Quantcast

Latest MedImmune Stories

2011-03-03 11:49:00

ROCKVILLE, Md., March 3, 2011 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) announced today that Maryland State Governor Martin O'Malley will visit the company's headquarters in Rockville, Maryland, on Monday, March 7, to celebrate the recently announced contract valued at up to $179 million. The Office of Biomedical Advanced Research and Development Authority (BARDA) within the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human...

2011-03-01 07:30:00

ROCKVILLE, Md., March 1, 2011 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) announced today that it has been awarded a contract valued at up to $179 million by the Office of Biomedical Advanced Research and Development Authority (BARDA) within the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services (HHS) for the advanced clinical and manufacturing development of recombinant vaccines for the prevention of seasonal and pandemic...

2011-03-01 01:35:00

VIENNA, March 1, 2011 /PRNewswire/ -- Today Intercell AG (VSE: ICLL) announced its financial results for Q4 and the preliminary results for the full financial year 2010 and presented an update on the Company's development programs. Increase in IXIARO®/JESPECT® sales by approximately 66% to EUR 12.8m for the full year 2010, due to increased sales in key travel markets and to U.S. military. EUR 255.2m net loss for the full year 2010 resulting mainly from...

2011-02-28 15:00:00

INCLINE VILLAGE, Nev., Feb. 28, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today reported financial results for the fourth quarter and full year ended December 31, 2010. Total revenues in 2010 were $345.0 million, compared to $318.2 million in 2009. Excluding 2009 royalty revenues for sales of Synagis® received from MedImmune, royalty revenues for 2010 increased 30 percent over 2009. For the fourth quarter of 2010, total revenues were $76.1 million,...

2011-02-16 06:00:00

GAITHERSBERG, Md. and INCLINE VILLAGE, Nev., Feb. 16, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (Nasdaq: PDLI) (PDL) today announced that PDL and MedImmune, LLC have entered into a definitive settlement agreement that resolves all legal disputes between them, including those relating to MedImmune's product Synagis® and PDL's patents known as the Queen et al. patents. Under the settlement agreement, PDL paid MedImmune $65 million on February 15, 2011 and will pay $27.5...

2011-02-09 08:00:00

ROCKVILLE, Md., Feb. 9, 2011 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that Dr. Gregory Glenn, Chief Medical Officer of Novavax, will be presenting safety and immunogenicity data from its pivotal 2009 A/H1N1 virus-like particle (VLP) pandemic influenza vaccine clinical trial in Mexico, at the invitation-only 7th WHO Meeting on Evaluation of Pandemic Influenza Vaccines in Clinical Trials. The meeting is being held February 17-18, 2011 at...

2011-02-08 07:44:00

-The Company launches the clinical development of its seasonal flu vaccine- QUEBEC CITY, Feb. 8 /PRNewswire-FirstCall/ - Medicago Inc. (TSX: MDG) a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced it has received Food and Drug Administration ("FDA") clearance for its phase I H1N1 influenza VLP vaccine candidate ("H1N1 vaccine") clinical trial in the...

2011-01-27 04:07:00

NEW YORK, Jan. 27, 2011 /PRNewswire/ -- Get content from AstraZeneca at: http://www.thenewsmarket.com/Releases/StoryDetailPage.aspx?GUID=0be570e4-bf68-4c0b-9777-4d22d679e195# Anglo-Swedish pharmaceutical company AstraZeneca announced that revenue for the full year was unchanged at constant exchange rates (CER) at $33,269 million. Strong revenue growth in markets outside the US (up 7% at CER) broadly offset the loss of more than $1.6 billion of revenue in the US from generic competition...

2011-01-27 01:47:00

LONDON, January 27, 2011 /PRNewswire-FirstCall/ -- AstraZeneca said its full-year results had outperformed guidance, with growth in emerging markets compensating for patent expiries and pricing pressures from Western governments. The company said a reallocation of resources had led to growth of 16 per cent in its emerging markets, led by China where sales broke through the $1bn mark for the first time. In an interview with http://www.cantos.com, David Brennan, CEO, said the...

2011-01-20 07:30:00

GAITHERSBURG, Md., Jan. 20, 2011 /PRNewswire/ -- MedImmune's Oncology group announced today preclinical results showing that MEDI-573, a targeted monoclonal antibody, broadly suppresses pathways that have been shown to play a critical role in the development and progression of many solid tumors. The study, published in the February 1 issue of Cancer Research (a journal of the American Association for Cancer Research), suggests that MEDI-573 inhibits multiple biological pathways related to...


Word of the Day
tesla
  • The unit of magnetic flux density in the International System of Units, equal to the magnitude of the magnetic field vector necessary to produce a force of one newton on a charge of one coulomb moving perpendicular to the direction of the magnetic field vector with a velocity of one meter per second. It is equivalent to one weber per square meter.
This word is named for Nikola Tesla, the inventor, engineer, and futurist.